Exact Non-Parametric Statistical Test for Pre-Clinical Data Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional statistical methods are inadequate for analyzing pre-clinical data characterized by small sample sizes, non-normal distributions, sparsity, skewness, and non-continuity, leading to inefficiencies and incorrect results in drug treatment efficacy assessments, particularly due to issues with family-wise type I error control and excessive computation times.
Innovation Solution
A computer-implemented method utilizing an EXACT, non-parametric, non-asymptotic statistical hypothesis test, such as the EXACT Mann-Whitney test, with an optional timeout feature to switch to a Monte Carlo approximation, combined with a Multiple Comparison Procedure like the Holm-Bonferroni Correction, to provide accurate and timely results for drug treatment efficacy analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional statistical methods (T-tests, ANOVA, Mann-Whitney test) are used to analyze pre-clinical data, then the analysis can be performed with standard software, but the results are inaccurate due to violations of assumptions (small sample sizes, non-normal distributions, sparsity, skewness, non-continuity)
Solution Approach 1:
The patent changes the fundamental parameters of the statistical test by using exact non-parametric methods (like exact Mann-Whitney U test) that do not assume normal distribution or continuous data. This allows accurate analysis of pre-clinical data with small sample sizes, sparsity, and non-continuity without requiring data transformation or approximation.
Solution Approach 2:
The patent replaces conventional parametric statistical mechanics with exact non-parametric statistical methods. Instead of relying on asymptotic approximations and normality assumptions, the system uses exact probability calculations that work directly with the actual data distribution, providing accurate p-values for small and sparse samples.
2Measurement precision
If exact non-parametric tests are used to analyze pre-clinical data, then accuracy is improved, but computation time becomes excessively long (hours or days)
Solution Approach 1:
The patent implements a dynamic test selection mechanism that adapts to the specific characteristics of the data and the computational resources available. The system can switch between exact non-parametric tests (for accuracy) and approximate methods (for speed) based on real-time conditions, making the analysis process flexible and efficient.
Solution Approach 2:
The patent applies partial exact testing only when necessary (e.g., when sample sizes are very small or data are highly sparse) and uses approximate methods for cases where exact computation would be excessively time-consuming. This selective application balances accuracy requirements with computational efficiency.
3Reliability
If multiple pairwise tests are performed to compare treatment groups, then comprehensive efficacy assessment is achieved, but family-wise type I error increases
Solution Approach 1:
The patent implements feedback mechanisms through multiple comparison procedures (MCP) that adjust the significance threshold based on the number of comparisons being made. This feedback loop controls the family-wise type I error rate by dynamically adjusting alpha levels to maintain overall error control across multiple testing scenarios.
Solution Approach 2:
The patent changes the significance threshold parameter dynamically based on the testing context. By adjusting the alpha level according to the number of comparisons and the specific data characteristics, the system maintains appropriate type I error control while still allowing comprehensive efficacy assessment across multiple treatment groups.
Data Source
AI summary
Methods and apparatus provide for: receiving pre-clinical data measured during drug treatment of a plurality of mammals including at least two treatment groups; performing at least one EXACT, non-parametric, statistical hypothesis test comparing the pre-clinical data for the at least two treatment groups; and performing a Multiple Comparison Procedure (MCP) on the pre-clinical data for at least two comparisons, where the EXACT, non-parametric, statistical hypothesis test and the MCP are conducted on the pre-clinical data to produce one or more p-values, each p-value representing whether an associated one of the treatment groups has experienced a statistically significant improvement or decline in one or more conditions of the mammals associated with the treatment.